DOP2024000136A - Vegf y proteína de fusión de unión a tie2 y sus usos - Google Patents

Vegf y proteína de fusión de unión a tie2 y sus usos

Info

Publication number
DOP2024000136A
DOP2024000136A DO2024000136A DO2024000136A DOP2024000136A DO P2024000136 A DOP2024000136 A DO P2024000136A DO 2024000136 A DO2024000136 A DO 2024000136A DO 2024000136 A DO2024000136 A DO 2024000136A DO P2024000136 A DOP2024000136 A DO P2024000136A
Authority
DO
Dominican Republic
Prior art keywords
fusion protein
vegf
tie2
vascular
binding fusion
Prior art date
Application number
DO2024000136A
Other languages
English (en)
Spanish (es)
Inventor
CHOO Minkyung
Kim Kwangsoo
HAN Sangyeul
DUROST Philip
Original Assignee
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of DOP2024000136A publication Critical patent/DOP2024000136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2024000136A 2022-01-13 2024-07-12 Vegf y proteína de fusión de unión a tie2 y sus usos DOP2024000136A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US202263335805P 2022-04-28 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000136A true DOP2024000136A (es) 2024-10-15

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000136A DOP2024000136A (es) 2022-01-13 2024-07-12 Vegf y proteína de fusión de unión a tie2 y sus usos

Country Status (16)

Country Link
US (1) US20230287109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463482A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884072B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250005053A (cg-RX-API-DMAC7.html)
AU (1) AU2023206363A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242904A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002106A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010934A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240342A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000136A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416581A (cg-RX-API-DMAC7.html)
IL (1) IL314219A (cg-RX-API-DMAC7.html)
JO (1) JOP20240158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008737A (cg-RX-API-DMAC7.html)
PE (1) PE20260003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023137395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2026036282A1 (en) * 2024-08-13 2026-02-19 Pentavision Biosciences Limited Multispecific fusion proteins targeting angiogenic factors
US20260226178A1 (en) * 2024-12-23 2026-08-06 Ingenia Therapeutics, Inc. Fusion Proteins Comprising a Tie2 Binding Domain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415533A1 (en) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
GEAP202416581A (en) 2024-12-10
JP7884072B2 (ja) 2026-07-02
WO2023137395A1 (en) 2023-07-20
AU2023206363A1 (en) 2024-08-15
CL2025002473A1 (es) 2025-11-14
MX2024008737A (es) 2024-09-11
US20230287109A1 (en) 2023-09-14
JOP20240158A1 (ar) 2024-07-14
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
EP4463482A1 (en) 2024-11-20
CL2024002106A1 (es) 2025-03-28
EP4463482A4 (en) 2026-05-06
CR20240342A (es) 2024-09-18
PE20260003A1 (es) 2026-01-06
CO2024010934A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
CO2024010934A2 (es) Vegf y proteína de fusión de unión a tie2 y sus usos
UY39049A (es) Composición para controlar las enfermedades de las plantas y método para controlar las enfermedades de las plantas
CL2021000873A1 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
Zhu et al. Melatonin promotes osteoblastic differentiation and regulates PDGF/AKT signaling pathway
UY39048A (es) Composición para controlar las enfermedades de las plantas y método para controlar las enfermedades de las plantas
NI201400024A (es) Agentes de ligación al factor de crecimiento endotelial vascular/ligando 4 similar a delta ( vegf/dll4) y usos de los mismos.
CO2023011853A2 (es) Anticuerpos anti-variable delta 1 de tcr
CO2022003078A2 (es) Composiciones y métodos para el tratamiento de infecciones virales
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
ES2169159T3 (es) Montaje para tratar vasos sanguineos.
CL2024001615A1 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
AR119722A1 (es) Métodos y composiciones para modular el empalme y la traducción
CL2022003390A1 (es) Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MX2018002000A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2023014407A (es) Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.
BR112019016300A2 (pt) ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
MX2020012925A (es) Producto inmunogeno que comprende il-4 y/o il-13 para el tratamiento de enfermedades asociadas con la expresion o actividad aberrante de il-4 y/o il 13.
CR20240389A (es) Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2
AR134365A1 (es) CONJUGADOS ANTICUERPO-FÁRMACO QUE SE DIRIGEN A EGFR / c-MET Y MÉTODOS DE PREPARACIÓN Y USOS DE ESTOS
EP4340880A4 (en) ANTIBODY-PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF AMYLOID DISORDERS
MX2023011480A (es) Conjugados anticuerpo anti-her2-fármaco y usos de estos.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
BR112022006560A2 (pt) Moduladores de atf6 e usos dos mesmos